Masimo Corporation (MASI) Stock Analysis

Q: What is the MASI stock price target?

Take-profit $175.36 (-1.9% upside). Target $175.36 (-1.9%), stop $178.14 (−0.4%), A.R:R -1.0:1.

HoldModerate ConfidenceUpdated 15 hr ago (May 20, 2026, 1:41 AM ET)

Healthcare · Medical Devices

$178.80-1.9% A.UpsideScore 5.8/10#10 of 40 Medical Devices

QualityF-score9 / 9FCF yield3.50%

Stop $178.14Target $175.36(resistance)A.R:R -1.0:1

Analyst target$180.00+0.7%4 analysts

Range unavailable (4 analysts)

Hold if already holding. Not a fresh buy at $178.80, but acceptable to hold if already in. Reasons: Concentration risk — Product: Masimo SET® platform and rainbow SET® platform; Concentration risk — Supplier: sole or limited source suppliers. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Wide-moat business. Accumulate on weakness. | News modifier -1 (STRONG_BUY_WAIT → HOLD_IF_HOLDING) Score 5.8/10, moderate confidence.

Passes 7/8 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, earnings proximity 77d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: moderate.

Recent Developments — Masimo Corporation

Latest news

Masimo Stockholders Approve Merger Agreement With Danaher, Mobius Merger Sub — benzinga May 4, 2026 positive
Masimo's Appeal Rejection, M5 Chip Push, China Smartphone Growth, Foldable iPhone: This Week In Appleverse — benzinga Apr 19, 2026 negative
Apple Scores Key Win As Trade Commission Rejects Masimo's Bid To Reinstate Apple Watch Import Ban — benzinga Apr 18, 2026 negative

Generated 2026-05-20T20:21:21Z.

Thesis

Rewards

V7 quality resilience bonus: +0.2 (Q=8.0 in RISK_OFF)

Sector modifier (Healthcare): +0.5

High-quality business

Risks

Concentration risk — Product: Masimo SET® platform and rainbow SET® platform

Concentration risk — Supplier: sole or limited source suppliers

Analyst target reached - limited upside remaining

Key Metrics

P/E (TTM)44.4

P/E (Fwd)27.1

Mkt Cap$9.4B

EV/EBITDA26.4

Profit Mgn4.9%

ROE25.0%

Rev Growth8.5%

Beta1.13

DividendNone

Rating analysts15

Quality Signals

Piotroski F9/9MoatWideCompounder✓

Options Flow

P/C0.46bullish

IV28%low

Concentration Risks(10-K Item 1A)

HIGHProductMasimo SET® platform and rainbow SET® platform
10-K Item 1A: 'We currently derive a significant portion of our revenue from our Masimo SET® platform, Masimo rainbow SET® platform and related products'
HIGHSuppliersole or limited source suppliers
10-K Item 1A: 'If we are unable to obtain key materials and components from sole or limited source suppliers, we will not be able to deliver our products to customers'

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

2 floor-breakers

Overall = weighted sum of the 10 dimension scores. Fundamentals (Value/Quality/Growth) carry 45%; market signals (Momentum/Sentiment/Insider/Peer) carry 40%; structure (Technical/Risk/Catalyst) carries 15%.

DimensionScoreWeightContribution

Value4.715%0.70

Quality8.015%1.20

Growth7.315%1.09

Momentum5.610%0.56

Sentiment5.010%0.50

Insider Activity6.710%0.67

Peer Rank3.310%0.33

Technical Setup4.05%0.20

Risk Profile7.75%0.39

Catalyst3.75%0.19

Overall (Σ contributions)5.83

Small float-rounding may cause last-digit differences between this sum and the displayed Overall.

Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static

Value Rank

1.9

Growth Rank

5.0

Quality Rank

6.5

Superior ROE vs peers

No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static

Surprise Avg

3.1

Earnings History

3.3

Erm

3.5

Earnings Timing

5.0

Earnings concerns: 2B/2M

GatesA.R:R -1.0=NEGATIVEMomentum 5.6>=5.5Insider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTEARNINGS PROXIMITY 77d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARSuitability: Moderate

RSI

59 · Neutral

↑ 20D MA↑ 50D MA↑ 200D MAGOLDEN CROSSSupport $178.16Resistance $178.94

Price Targets

$178

$175

A.Upside-1.9%

A.R:R-1.0:1

Position Sizing

ConvictionNone

Suggested %0.5%

Max %1%

RegimeRisk-Off

Risk Alerts

! Target reached (-14.4% upside)

! NEWS_MOD=-1: STRONG_BUY_WAIT → HOLD_IF_HOLDING

! Negative risk/reward — downside exceeds upside

Earnings

2/4 beats

Next Earnings2026-08-04 (77d)

Verdict History

reverse chrono — latest first

Loading history...

Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.

Frequently Asked Questions

Is MASI stock a buy right now?

Hold if already holding. Not a fresh buy at $178.80, but acceptable to hold if already in. Reasons: Concentration risk — Product: Masimo SET® platform and rainbow SET® platform; Concentration risk — Supplier: sole or limited source suppliers. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Wide-moat business. Accumulate on weakness. | News modifier -1 (STRONG_BUY_WAIT → HOLD_IF_HOLDING) Target $175.36 (-1.9%), stop $178.14 (−0.4%), A.R:R -1.0:1. Score 5.8/10, moderate confidence.

What is the MASI stock price target?

Take-profit target: $175.36 (-1.9% upside). Target $175.36 (-1.9%), stop $178.14 (−0.4%), A.R:R -1.0:1. Stop-loss: $178.14.

What are the risks of investing in MASI?

Concentration risk — Product: Masimo SET® platform and rainbow SET® platform; Concentration risk — Supplier: sole or limited source suppliers; Analyst target reached - limited upside remaining.

Is MASI overvalued or undervalued?

Masimo Corporation trades at a P/E of 44.4 (forward 27.1). TrendMatrix value score: 4.7/10. Verdict: Hold.

What do analysts say about MASI?

15 analysts cover MASI with a consensus score of 3.5/5. Average price target: $180.

What does Masimo Corporation do?Masimo develops and sells noninvasive patient monitoring technologies including Masimo SET pulse oximetry, rainbow...

Masimo develops and sells noninvasive patient monitoring technologies including Masimo SET pulse oximetry, rainbow Pulse CO-Oximetry, and hospital automation/connectivity solutions to hospitals and care providers globally. The company sold its non-healthcare consumer business (Sound United) to Samsung/Harman in September 2025 and entered a pending merger agreement with Danaher Corporation at $180/share announced February 16, 2026.